Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Botswana | 147 | 2024 | 1040 | 4.850 |
Why?
|
HIV Infections | 171 | 2024 | 17275 | 4.080 |
Why?
|
HIV-1 | 79 | 2024 | 6850 | 3.000 |
Why?
|
Pregnancy Complications, Infectious | 43 | 2024 | 2125 | 2.310 |
Why?
|
Anti-HIV Agents | 56 | 2024 | 4504 | 2.130 |
Why?
|
Anti-Retroviral Agents | 32 | 2023 | 1780 | 1.810 |
Why?
|
Infectious Disease Transmission, Vertical | 29 | 2024 | 1348 | 1.510 |
Why?
|
Viral Load | 41 | 2024 | 3321 | 1.450 |
Why?
|
HIV Seropositivity | 14 | 2023 | 960 | 1.300 |
Why?
|
Antiretroviral Therapy, Highly Active | 32 | 2024 | 1895 | 1.230 |
Why?
|
Drug Resistance, Viral | 16 | 2024 | 860 | 1.170 |
Why?
|
Premature Birth | 16 | 2023 | 1771 | 1.080 |
Why?
|
Circumcision, Male | 6 | 2020 | 148 | 1.080 |
Why?
|
RNA, Viral | 26 | 2021 | 2836 | 0.990 |
Why?
|
Heterocyclic Compounds, 3-Ring | 6 | 2024 | 278 | 0.880 |
Why?
|
Zidovudine | 18 | 2024 | 624 | 0.860 |
Why?
|
Hepatitis B | 7 | 2024 | 701 | 0.800 |
Why?
|
Benzoxazines | 9 | 2024 | 309 | 0.790 |
Why?
|
Breast Feeding | 16 | 2023 | 1355 | 0.750 |
Why?
|
CD4 Lymphocyte Count | 30 | 2023 | 2569 | 0.720 |
Why?
|
Nevirapine | 14 | 2024 | 273 | 0.690 |
Why?
|
Reverse Transcriptase Inhibitors | 8 | 2020 | 619 | 0.660 |
Why?
|
HIV | 14 | 2023 | 1581 | 0.650 |
Why?
|
Pregnancy Outcome | 18 | 2024 | 2907 | 0.620 |
Why?
|
Hepatitis B virus | 8 | 2024 | 520 | 0.600 |
Why?
|
Pregnancy | 72 | 2024 | 29742 | 0.580 |
Why?
|
Stillbirth | 12 | 2024 | 368 | 0.580 |
Why?
|
Oxazines | 7 | 2024 | 341 | 0.540 |
Why?
|
Infant, Newborn | 52 | 2024 | 26183 | 0.510 |
Why?
|
Phylogeny | 14 | 2024 | 2774 | 0.500 |
Why?
|
Pyridones | 8 | 2024 | 784 | 0.470 |
Why?
|
HIV Antibodies | 13 | 2024 | 1300 | 0.470 |
Why?
|
Alkynes | 9 | 2024 | 312 | 0.460 |
Why?
|
Lamivudine | 6 | 2024 | 362 | 0.460 |
Why?
|
Genotype | 19 | 2024 | 12945 | 0.450 |
Why?
|
Cyclopropanes | 9 | 2024 | 431 | 0.440 |
Why?
|
HIV Integrase Inhibitors | 5 | 2024 | 165 | 0.420 |
Why?
|
Mass Screening | 6 | 2020 | 5427 | 0.390 |
Why?
|
Female | 154 | 2024 | 390323 | 0.380 |
Why?
|
DNA, Viral | 11 | 2023 | 2194 | 0.380 |
Why?
|
Maternal-Fetal Exchange | 3 | 2018 | 463 | 0.370 |
Why?
|
Adult | 111 | 2024 | 219935 | 0.370 |
Why?
|
Herpes Genitalis | 6 | 2011 | 142 | 0.360 |
Why?
|
Proviruses | 5 | 2023 | 313 | 0.350 |
Why?
|
Humans | 190 | 2024 | 758406 | 0.340 |
Why?
|
Sexual Partners | 7 | 2018 | 791 | 0.330 |
Why?
|
Infant Formula | 5 | 2021 | 193 | 0.330 |
Why?
|
Pregnancy Complications | 5 | 2023 | 2942 | 0.330 |
Why?
|
Child Development | 6 | 2019 | 2285 | 0.330 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 403 | 0.320 |
Why?
|
Prevalence | 24 | 2024 | 15651 | 0.320 |
Why?
|
Prenatal Exposure Delayed Effects | 7 | 2024 | 2496 | 0.320 |
Why?
|
Hepatitis Delta Virus | 2 | 2024 | 24 | 0.300 |
Why?
|
Infant | 35 | 2024 | 36055 | 0.290 |
Why?
|
Herpesvirus 2, Human | 6 | 2011 | 191 | 0.290 |
Why?
|
Viremia | 4 | 2024 | 706 | 0.290 |
Why?
|
Mining | 1 | 2007 | 91 | 0.290 |
Why?
|
Milk, Human | 5 | 2012 | 483 | 0.280 |
Why?
|
Piperazines | 6 | 2024 | 2511 | 0.270 |
Why?
|
Neural Tube Defects | 2 | 2019 | 254 | 0.270 |
Why?
|
Disease Transmission, Infectious | 3 | 2019 | 557 | 0.270 |
Why?
|
Acyclovir | 4 | 2011 | 268 | 0.270 |
Why?
|
Young Adult | 42 | 2024 | 58808 | 0.260 |
Why?
|
Incidence | 15 | 2023 | 21272 | 0.250 |
Why?
|
Uterine Cervical Dysplasia | 2 | 2023 | 384 | 0.250 |
Why?
|
Hepatitis D | 1 | 2024 | 23 | 0.240 |
Why?
|
Mutation | 12 | 2024 | 29915 | 0.240 |
Why?
|
Maternal Mortality | 2 | 2024 | 300 | 0.240 |
Why?
|
Male | 85 | 2024 | 358747 | 0.220 |
Why?
|
Wolves | 1 | 2023 | 10 | 0.220 |
Why?
|
Dog Diseases | 1 | 2023 | 141 | 0.200 |
Why?
|
Dideoxynucleosides | 2 | 2012 | 131 | 0.200 |
Why?
|
Epidemics | 2 | 2022 | 512 | 0.190 |
Why?
|
Occupational Health | 1 | 2007 | 805 | 0.190 |
Why?
|
Hepatitis B Surface Antigens | 4 | 2023 | 301 | 0.190 |
Why?
|
Leukocytes, Mononuclear | 3 | 2023 | 1826 | 0.180 |
Why?
|
HIV Reverse Transcriptase | 2 | 2019 | 212 | 0.180 |
Why?
|
Rotavirus Vaccines | 1 | 2020 | 62 | 0.170 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 206 | 0.170 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2014 | 662 | 0.170 |
Why?
|
Mothers | 5 | 2024 | 2189 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2024 | 3941 | 0.170 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2020 | 131 | 0.170 |
Why?
|
Postpartum Period | 4 | 2017 | 1167 | 0.170 |
Why?
|
Disease Reservoirs | 1 | 2019 | 121 | 0.170 |
Why?
|
HIV Antigens | 2 | 2018 | 325 | 0.170 |
Why?
|
Treatment Failure | 7 | 2024 | 2640 | 0.160 |
Why?
|
Antiviral Agents | 6 | 2024 | 3056 | 0.160 |
Why?
|
Vaccines, Conjugate | 1 | 2020 | 328 | 0.160 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 3 | 2023 | 368 | 0.160 |
Why?
|
HIV Seronegativity | 2 | 2011 | 211 | 0.160 |
Why?
|
Paternal Exposure | 1 | 2019 | 94 | 0.160 |
Why?
|
Hepatitis B Antibodies | 3 | 2023 | 157 | 0.160 |
Why?
|
Rural Population | 5 | 2024 | 2254 | 0.160 |
Why?
|
Drug Therapy, Combination | 11 | 2019 | 6293 | 0.160 |
Why?
|
Quarantine | 1 | 2020 | 176 | 0.160 |
Why?
|
Obstetric Labor, Premature | 1 | 2020 | 274 | 0.150 |
Why?
|
Adolescent | 26 | 2023 | 87892 | 0.150 |
Why?
|
Virus Activation | 1 | 2019 | 319 | 0.150 |
Why?
|
Tuberculosis | 3 | 2019 | 2001 | 0.150 |
Why?
|
Middle Aged | 40 | 2024 | 219568 | 0.150 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 469 | 0.140 |
Why?
|
Transients and Migrants | 1 | 2020 | 162 | 0.140 |
Why?
|
Pneumococcal Vaccines | 1 | 2020 | 397 | 0.140 |
Why?
|
Receptors, CXCR4 | 2 | 2012 | 727 | 0.140 |
Why?
|
Papillomavirus Infections | 2 | 2023 | 1612 | 0.140 |
Why?
|
Enzyme Assays | 1 | 2017 | 104 | 0.140 |
Why?
|
Syphilis | 1 | 2019 | 243 | 0.140 |
Why?
|
Pyridazines | 1 | 2018 | 200 | 0.140 |
Why?
|
Gestational Age | 2 | 2018 | 3565 | 0.140 |
Why?
|
Disease Progression | 8 | 2017 | 13468 | 0.130 |
Why?
|
Fetus | 2 | 2020 | 1859 | 0.130 |
Why?
|
Diarrhea, Infantile | 1 | 2016 | 101 | 0.130 |
Why?
|
Genes, env | 2 | 2013 | 95 | 0.130 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2014 | 2197 | 0.130 |
Why?
|
Cervix Uteri | 1 | 2020 | 583 | 0.130 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 282 | 0.130 |
Why?
|
Congenital Abnormalities | 2 | 2019 | 704 | 0.130 |
Why?
|
Antimalarials | 1 | 2022 | 905 | 0.130 |
Why?
|
Antibody Affinity | 1 | 2016 | 245 | 0.130 |
Why?
|
Serologic Tests | 1 | 2018 | 383 | 0.130 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2019 | 3992 | 0.130 |
Why?
|
Antibodies, Neutralizing | 5 | 2024 | 1931 | 0.130 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2021 | 517 | 0.130 |
Why?
|
Pregnancy, Unplanned | 1 | 2016 | 88 | 0.120 |
Why?
|
Nervous System | 1 | 2018 | 543 | 0.120 |
Why?
|
Asymptomatic Infections | 1 | 2015 | 131 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1160 | 0.120 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2017 | 338 | 0.110 |
Why?
|
Child | 17 | 2024 | 79818 | 0.110 |
Why?
|
Contraception Behavior | 1 | 2016 | 181 | 0.110 |
Why?
|
Diarrhea | 1 | 2020 | 1317 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2021 | 5199 | 0.110 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2023 | 4353 | 0.110 |
Why?
|
Travel | 1 | 2019 | 785 | 0.110 |
Why?
|
Deficiency Diseases | 1 | 2013 | 74 | 0.110 |
Why?
|
Pregnant Women | 3 | 2023 | 562 | 0.110 |
Why?
|
Hepatitis B e Antigens | 2 | 2023 | 133 | 0.110 |
Why?
|
Causality | 1 | 2019 | 1241 | 0.110 |
Why?
|
Respiratory System | 1 | 2016 | 557 | 0.110 |
Why?
|
AIDS Serodiagnosis | 2 | 2020 | 220 | 0.110 |
Why?
|
Immunoassay | 1 | 2016 | 746 | 0.110 |
Why?
|
Malaria | 1 | 2022 | 1226 | 0.100 |
Why?
|
Vaccination | 2 | 2023 | 3355 | 0.100 |
Why?
|
Amino Acid Substitution | 3 | 2011 | 1734 | 0.100 |
Why?
|
Hypertension | 3 | 2023 | 8499 | 0.100 |
Why?
|
Prenatal Care | 1 | 2020 | 1129 | 0.100 |
Why?
|
Immunity, Innate | 3 | 2022 | 3047 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2017 | 1177 | 0.100 |
Why?
|
Mastitis | 1 | 2012 | 43 | 0.100 |
Why?
|
HIV Envelope Protein gp120 | 3 | 2016 | 914 | 0.100 |
Why?
|
Plasma | 1 | 2015 | 584 | 0.100 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 12440 | 0.100 |
Why?
|
Counseling | 2 | 2022 | 1541 | 0.100 |
Why?
|
Birth Weight | 3 | 2023 | 2097 | 0.100 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7403 | 0.100 |
Why?
|
Placental Insufficiency | 1 | 2012 | 50 | 0.100 |
Why?
|
Hemoglobins | 1 | 2018 | 1519 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2018 | 1474 | 0.100 |
Why?
|
Evolution, Molecular | 2 | 2011 | 1885 | 0.100 |
Why?
|
Equipment and Supplies | 1 | 2014 | 273 | 0.100 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3142 | 0.100 |
Why?
|
Infant, Small for Gestational Age | 3 | 2021 | 460 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 611 | 0.100 |
Why?
|
Hospitalization | 6 | 2021 | 10652 | 0.100 |
Why?
|
Attitude to Health | 1 | 2020 | 2026 | 0.090 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 2016 | 0.090 |
Why?
|
Cross-Sectional Studies | 11 | 2023 | 25956 | 0.090 |
Why?
|
Carotid Artery Diseases | 1 | 2017 | 872 | 0.090 |
Why?
|
Selenium | 1 | 2013 | 416 | 0.090 |
Why?
|
Immunoglobulin M | 3 | 2023 | 1529 | 0.090 |
Why?
|
Prospective Studies | 14 | 2023 | 54137 | 0.090 |
Why?
|
Condoms | 3 | 2022 | 328 | 0.090 |
Why?
|
Drug Resistance, Bacterial | 1 | 2017 | 1055 | 0.090 |
Why?
|
Developmental Disabilities | 2 | 2016 | 1504 | 0.090 |
Why?
|
AIDS Vaccines | 1 | 2016 | 895 | 0.090 |
Why?
|
Drug Administration Schedule | 5 | 2018 | 4839 | 0.080 |
Why?
|
Didanosine | 1 | 2009 | 151 | 0.080 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1263 | 0.080 |
Why?
|
Valine | 1 | 2011 | 408 | 0.080 |
Why?
|
Cytokines | 2 | 2015 | 7338 | 0.080 |
Why?
|
Mutation, Missense | 3 | 2013 | 2564 | 0.080 |
Why?
|
Child, Preschool | 10 | 2024 | 42062 | 0.080 |
Why?
|
Alphapapillomavirus | 1 | 2011 | 219 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2019 | 7818 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1201 | 0.080 |
Why?
|
Cohort Studies | 13 | 2021 | 41256 | 0.080 |
Why?
|
Sequence Analysis, DNA | 7 | 2015 | 4711 | 0.080 |
Why?
|
Intention to Treat Analysis | 3 | 2016 | 414 | 0.080 |
Why?
|
Health Services Research | 2 | 2019 | 1812 | 0.080 |
Why?
|
Directive Counseling | 1 | 2009 | 171 | 0.080 |
Why?
|
Case-Control Studies | 8 | 2021 | 22029 | 0.080 |
Why?
|
Longitudinal Studies | 8 | 2020 | 14490 | 0.070 |
Why?
|
Receptors, Cell Surface | 1 | 2017 | 2825 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 6 | 2016 | 6493 | 0.070 |
Why?
|
Hospitals, District | 2 | 2019 | 113 | 0.070 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2014 | 831 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2658 | 0.070 |
Why?
|
Risk Factors | 16 | 2020 | 73809 | 0.070 |
Why?
|
Antigens, CD | 1 | 2017 | 3997 | 0.070 |
Why?
|
Patient Compliance | 5 | 2010 | 2685 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2021 | 9160 | 0.070 |
Why?
|
Acidosis, Lactic | 1 | 2007 | 145 | 0.070 |
Why?
|
Dietary Supplements | 2 | 2022 | 3387 | 0.070 |
Why?
|
Genetic Linkage | 1 | 2011 | 2381 | 0.070 |
Why?
|
Nitriles | 2 | 2023 | 957 | 0.070 |
Why?
|
Africa | 3 | 2017 | 706 | 0.060 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 39 | 0.060 |
Why?
|
Social Perception | 1 | 2009 | 432 | 0.060 |
Why?
|
Truth Disclosure | 1 | 2009 | 432 | 0.060 |
Why?
|
Vitamins | 1 | 2013 | 1632 | 0.060 |
Why?
|
Retrospective Studies | 12 | 2023 | 80168 | 0.060 |
Why?
|
Models, Statistical | 1 | 2020 | 5070 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1377 | 0.060 |
Why?
|
Population Surveillance | 3 | 2019 | 2606 | 0.060 |
Why?
|
Stereotyping | 1 | 2006 | 240 | 0.060 |
Why?
|
Pneumonia | 1 | 2016 | 2129 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2021 | 12262 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 2 | 2020 | 787 | 0.060 |
Why?
|
Neonatal Screening | 2 | 2020 | 594 | 0.060 |
Why?
|
Pregnancy Rate | 1 | 2007 | 649 | 0.060 |
Why?
|
Acetic Acid | 1 | 2023 | 60 | 0.060 |
Why?
|
Time Factors | 9 | 2019 | 39872 | 0.060 |
Why?
|
Pre-Eclampsia | 1 | 2013 | 1227 | 0.060 |
Why?
|
Hepatitis B Core Antigens | 1 | 2023 | 88 | 0.050 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5404 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2018 | 4412 | 0.050 |
Why?
|
Parturition | 2 | 2019 | 446 | 0.050 |
Why?
|
Tropism | 1 | 2023 | 43 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2716 | 0.050 |
Why?
|
Heterosexuality | 2 | 2019 | 301 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2013 | 3208 | 0.050 |
Why?
|
Colposcopy | 1 | 2023 | 150 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3196 | 0.050 |
Why?
|
HIV Protease Inhibitors | 2 | 2018 | 432 | 0.050 |
Why?
|
Diketopiperazines | 1 | 2022 | 24 | 0.050 |
Why?
|
Withholding Treatment | 2 | 2019 | 610 | 0.050 |
Why?
|
Viral Tropism | 1 | 2023 | 102 | 0.050 |
Why?
|
Infant Mortality | 3 | 2014 | 757 | 0.050 |
Why?
|
Genome, Viral | 2 | 2020 | 658 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2201 | 0.050 |
Why?
|
Microbial Sensitivity Tests | 2 | 2018 | 1945 | 0.050 |
Why?
|
Anemia | 1 | 2011 | 1504 | 0.050 |
Why?
|
Workplace | 1 | 2007 | 857 | 0.050 |
Why?
|
Americas | 1 | 2021 | 111 | 0.050 |
Why?
|
Chloroquine | 1 | 2022 | 274 | 0.050 |
Why?
|
Vitamin D | 1 | 2014 | 3283 | 0.050 |
Why?
|
E-Selectin | 1 | 2023 | 576 | 0.050 |
Why?
|
Treatment Outcome | 11 | 2018 | 64378 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2014 | 3175 | 0.040 |
Why?
|
Feces | 2 | 2017 | 1456 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2023 | 691 | 0.040 |
Why?
|
Immunoenzyme Techniques | 2 | 2013 | 1705 | 0.040 |
Why?
|
Databases, Nucleic Acid | 1 | 2021 | 204 | 0.040 |
Why?
|
Cervical Length Measurement | 1 | 2020 | 45 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2018 | 2697 | 0.040 |
Why?
|
Placenta | 2 | 2023 | 1702 | 0.040 |
Why?
|
Micronutrients | 1 | 2022 | 381 | 0.040 |
Why?
|
Monocytes | 2 | 2019 | 2570 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2023 | 1125 | 0.040 |
Why?
|
Pyrimidines | 2 | 2023 | 3006 | 0.040 |
Why?
|
Neutropenia | 2 | 2017 | 884 | 0.040 |
Why?
|
Anthropometry | 2 | 2016 | 1347 | 0.040 |
Why?
|
Nucleosides | 1 | 2019 | 131 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14641 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39059 | 0.040 |
Why?
|
Molecular Sequence Data | 4 | 2013 | 17617 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7590 | 0.040 |
Why?
|
Contact Tracing | 1 | 2020 | 271 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 743 | 0.040 |
Why?
|
Dogs | 1 | 2023 | 3840 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2019 | 442 | 0.040 |
Why?
|
Selection Bias | 1 | 2019 | 357 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2015 | 5331 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10146 | 0.040 |
Why?
|
Government Programs | 1 | 2019 | 279 | 0.040 |
Why?
|
Biometry | 1 | 2020 | 559 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 814 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 1 | 2020 | 732 | 0.040 |
Why?
|
Thailand | 1 | 2017 | 288 | 0.040 |
Why?
|
Epitopes | 1 | 2023 | 2502 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3446 | 0.030 |
Why?
|
Triage | 1 | 2023 | 986 | 0.030 |
Why?
|
Fetal Death | 1 | 2018 | 434 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10112 | 0.030 |
Why?
|
Inpatients | 2 | 2019 | 2551 | 0.030 |
Why?
|
Bayes Theorem | 2 | 2017 | 2322 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2017 | 415 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1754 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1593 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2022 | 5484 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2020 | 2176 | 0.030 |
Why?
|
Folic Acid | 1 | 2022 | 1309 | 0.030 |
Why?
|
United Nations | 1 | 2016 | 150 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 17768 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9599 | 0.030 |
Why?
|
Base Sequence | 2 | 2019 | 12436 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2017 | 604 | 0.030 |
Why?
|
Escherichia coli | 2 | 2017 | 4215 | 0.030 |
Why?
|
Qualitative Research | 2 | 2019 | 2976 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 856 | 0.030 |
Why?
|
World Health Organization | 1 | 2020 | 1312 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2020 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2022 | 1329 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 842 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3420 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2017 | 856 | 0.030 |
Why?
|
Immunization, Passive | 1 | 2016 | 616 | 0.030 |
Why?
|
Iron | 1 | 2022 | 1786 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 859 | 0.030 |
Why?
|
Brazil | 1 | 2017 | 1217 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 644 | 0.030 |
Why?
|
Contraceptives, Oral | 1 | 2016 | 554 | 0.030 |
Why?
|
Virus Replication | 1 | 2021 | 2430 | 0.030 |
Why?
|
Intention | 1 | 2016 | 345 | 0.030 |
Why?
|
Social Stigma | 1 | 2019 | 763 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2015 | 328 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 3801 | 0.030 |
Why?
|
Ultrasonography, Prenatal | 1 | 2020 | 1745 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12096 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 642 | 0.030 |
Why?
|
Gene Frequency | 1 | 2019 | 3612 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2013 | 222 | 0.020 |
Why?
|
Birth Certificates | 1 | 2011 | 71 | 0.020 |
Why?
|
Specimen Handling | 1 | 2016 | 707 | 0.020 |
Why?
|
Caregivers | 1 | 2024 | 2225 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2021 | 2016 | 0.020 |
Why?
|
Geography | 1 | 2013 | 660 | 0.020 |
Why?
|
Genetic Variation | 2 | 2019 | 6548 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 7985 | 0.020 |
Why?
|
Placebos | 1 | 2015 | 1661 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1067 | 0.020 |
Why?
|
Algorithms | 3 | 2020 | 13961 | 0.020 |
Why?
|
India | 1 | 2017 | 2329 | 0.020 |
Why?
|
Family Characteristics | 1 | 2016 | 1000 | 0.020 |
Why?
|
Community Health Services | 1 | 2016 | 656 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2020 | 6068 | 0.020 |
Why?
|
Goals | 1 | 2016 | 707 | 0.020 |
Why?
|
Health Personnel | 2 | 2020 | 3312 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1368 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2012 | 487 | 0.020 |
Why?
|
Lactation | 1 | 2012 | 397 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2012 | 13447 | 0.020 |
Why?
|
Developing Countries | 2 | 2015 | 2866 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 557 | 0.020 |
Why?
|
Neoplasms | 2 | 2015 | 22032 | 0.020 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2012 | 351 | 0.020 |
Why?
|
Body Height | 1 | 2016 | 1567 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3211 | 0.020 |
Why?
|
Spouses | 1 | 2011 | 279 | 0.020 |
Why?
|
Sex Factors | 2 | 2014 | 10504 | 0.020 |
Why?
|
Health Care Costs | 1 | 2022 | 3245 | 0.020 |
Why?
|
Perinatal Care | 1 | 2011 | 242 | 0.020 |
Why?
|
Virus Internalization | 1 | 2012 | 494 | 0.020 |
Why?
|
Seasons | 1 | 2014 | 1519 | 0.020 |
Why?
|
Sequence Homology | 1 | 2008 | 195 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2013 | 643 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8553 | 0.020 |
Why?
|
Capsid Proteins | 1 | 2011 | 467 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2012 | 2753 | 0.020 |
Why?
|
Kenya | 1 | 2011 | 749 | 0.020 |
Why?
|
Body Size | 1 | 2011 | 462 | 0.020 |
Why?
|
Unsafe Sex | 1 | 2010 | 238 | 0.020 |
Why?
|
Blood Pressure | 1 | 2023 | 8451 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2011 | 823 | 0.020 |
Why?
|
Campylobacter jejuni | 1 | 2007 | 25 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2011 | 754 | 0.020 |
Why?
|
Peru | 1 | 2011 | 884 | 0.020 |
Why?
|
Drug Tolerance | 1 | 2009 | 367 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5862 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3615 | 0.020 |
Why?
|
Haemophilus influenzae | 1 | 2007 | 180 | 0.020 |
Why?
|
Family Planning Services | 1 | 2010 | 265 | 0.020 |
Why?
|
Lactates | 1 | 2007 | 404 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2007 | 573 | 0.020 |
Why?
|
Risk Assessment | 2 | 2018 | 23884 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2011 | 868 | 0.020 |
Why?
|
Motivation | 1 | 2016 | 1996 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2016 | 2158 | 0.020 |
Why?
|
South Africa | 1 | 2011 | 1821 | 0.020 |
Why?
|
Point Mutation | 1 | 2011 | 1593 | 0.020 |
Why?
|
Bacteria | 1 | 2016 | 2197 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1296 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2058 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2007 | 1060 | 0.020 |
Why?
|
Logistic Models | 2 | 2013 | 13276 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1651 | 0.020 |
Why?
|
Medication Adherence | 1 | 2017 | 2155 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 15773 | 0.020 |
Why?
|
Body Weight | 1 | 2016 | 4603 | 0.020 |
Why?
|
Aged | 4 | 2023 | 168218 | 0.020 |
Why?
|
Community Health Centers | 1 | 2008 | 461 | 0.010 |
Why?
|
Surgical Wound Infection | 1 | 2014 | 1526 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1765 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2017 | 7021 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1878 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6157 | 0.010 |
Why?
|
Pregnancy Trimester, Third | 1 | 2007 | 582 | 0.010 |
Why?
|
Helicobacter pylori | 1 | 2007 | 376 | 0.010 |
Why?
|
Host-Pathogen Interactions | 1 | 2012 | 1444 | 0.010 |
Why?
|
Focus Groups | 1 | 2009 | 1384 | 0.010 |
Why?
|
Immunoglobulin A | 1 | 2007 | 979 | 0.010 |
Why?
|
Sequence Analysis, RNA | 1 | 2011 | 2001 | 0.010 |
Why?
|
Labor, Obstetric | 1 | 2007 | 321 | 0.010 |
Why?
|
Animals | 3 | 2023 | 167768 | 0.010 |
Why?
|
Sexually Transmitted Diseases | 1 | 2009 | 663 | 0.010 |
Why?
|
Immunologic Factors | 1 | 2012 | 1585 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2007 | 1829 | 0.010 |
Why?
|
Marital Status | 1 | 2003 | 432 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16534 | 0.010 |
Why?
|
Streptococcus pneumoniae | 1 | 2007 | 732 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2457 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2007 | 1468 | 0.010 |
Why?
|
Occupations | 1 | 2003 | 515 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2012 | 5098 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2690 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7225 | 0.010 |
Why?
|
Health Promotion | 1 | 2010 | 2204 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18358 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12604 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2003 | 2676 | 0.010 |
Why?
|
Educational Status | 1 | 2003 | 2513 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2006 | 6821 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 4244 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2007 | 4540 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29557 | 0.010 |
Why?
|
United States | 2 | 2011 | 72136 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15785 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2017 | 58683 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12075 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 15399 | 0.000 |
Why?
|